FDA panel unanimously recommends approval of Valeant’s brodalumab with conditions
July 20, 2016Research and Development, Sales and Marketing FDA, Valeant, brodalumab
Valeant has announced that the US Food and Drug Administration’s (FDA) dermatologic and ophthalmic drugs advisory committee has recommended brodalumab …
Celgene boosts cancer portfolio with deal worth up to $2.5 billion with Jounce Therapeutics
July 19, 2016Research and Development, Sales and Marketing Celgene, jounce
Celgene has entered into a collaboration with Jounce Therapeutics that will see the pair jointly develop and commercialise Jounce’s lead …
Teva sells $15 billion in bonds to fund Allergan generics deal
July 19, 2016Manufacturing and Production, Sales and Marketing Allergan, Teva, bonds, generics
Teva Pharmaceuticals has announced that it has successfully finalised a bond sale totalling $15 billion that will help to fund …
Opdivo to go before EU, US regulators in head and neck cancer
July 19, 2016Manufacturing and Production, Research and Development EMA, EU, FDA, US, head and neck cancer, opdivo
Bristol-Myers Squibb has announced that its lead oncology drug, Opdivo (nivolumab), is set to go before regulators in the US …
Novartis lowers core operating profit outlook in Q2 results
July 19, 2016Manufacturing and Production, Research and Development, Sales and Marketing 2016, Novartis, Q2, results
Novartis has warned that its profits may decline this year as it issued second quarter results, with generic competition for …
New data shows superior viral suppression for Triumeq in women with HIV
July 18, 2016Manufacturing and Production, Research and Development Triumeq, ViiV Healthcare
ViiV Healthcare has presented late-stage data showing superior efficacy for combination treatment Triumeq (dolutegravir/abacavir/lamivudine) compared with atazanavir, plus other treatments, …
AstraZeneca presents positive Phase III results for lung cancer drug Tagrisso
July 18, 2016Manufacturing and Production, Research and Development AstraZeneca, Tagrisso
AstraZeneca has presented results from the latest Phase III trial evaluating Tagrisso (osimertinib) as a second line treatment for patients …
Roche’s lymphoma drug fails to beat rivals in Phase III trial
July 18, 2016Research and Development, Sales and Marketing Roche, lymphoma, phase III
Roche has announced that a Phase III trial evaluating Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated diffuse large B-cell lymphoma …
Samsung Bioepis Humira biosimilar gets accepted for EMA review
July 18, 2016Research and Development, Sales and Marketing EMA, Humira, Samsung Bioepis, application
The European Medicines Agency (EMA) has accepted for review the marketing authorisation application from Samsung Bioepis for their biosimilar version …
FDA approves first extended depth of focus lenses for people with cataracts
July 18, 2016Research and Development, Sales and Marketing Abbott, FDA, cataracts
Abbott has announced that the Tecnis Symfony Intraocular Lenses for the treatment of cataracts has been approved by the US …
Valeant’s psoriasis drug “difficult to assess”, according to FDA staff
July 18, 2016Research and Development, Sales and Marketing FDA, Valeant, psoriasis
Staff at the US Food and Drug Administration have expressed concerns over Valeant’s psoriasis candidate, brodalumab, due to the potential …
Patient death in gene therapy trial sends Ziopharm stocks falling
July 18, 2016Research and Development, Sales and Marketing ziopharm
Ziopharm Oncology has issued a statement following the death of a patient enrolled on a Phase I clinical trial for …
UK medical charity sells part of interest in MSD’s Keytruda for $150 million
July 15, 2016Research and Development, Sales and Marketing MSD, Merck, keytruda
UK medical research charity MRC Technology sold part of its royalty interest in US pharma major MSD’s (NYSE: MRK) immunotherapy …
Weekly Movers: CytRx, Coherus BioSciences, Juno Therapeutics…
July 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Coherus BioSciences, GW Pharmaceuticals, Sage Therapeutics, Share price, Shares, Stock Markets, cytrx, juno therapeutics
Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing late-stage results for its lead …
Nice rejects United Therapeutics’ cancer drug
July 15, 2016Medical Communications, Research and Development NICE, United Therapeutics, Unituxin, neuroblastoma
The National Institute for Health and Care Excellence (Nice) rejected United Therapeutics’ (Nasdaq: UTHR) Unituxin (dinutuximab) in combination therapy to …
Bayer adds extra $2 billion to Monsanto bid
July 15, 2016Medical Communications, Sales and Marketing Bayer, monsanto
German pharma company Bayer (ETR: BAYN) have upped their bid for Monsanto (NYSE: MON) to $64 billion, putting pressure on …
Busy week at Juno Therapeutics ends with takeover of RedoxTherapies
July 15, 2016Medical Communications, Research and Development, Sales and Marketing juno therapeutics, redoxtherapies, takeover, vipadenant
Juno Therapeutics (NASDAQ: JUNO) has announced the acquisition of RedoxTherapies, adding its lead cancer drug candidate, vipadenant, to its portfolio.
Teva looking at up to $25 billion in bond sale to fund Allergan’s generic-unit buy – reports
July 15, 2016Medical Communications, Sales and Marketing Allergan, Financial, Teva, US regulators, bond sale, deal
Israeli drug firm Teva (NYSE: TEVA) is looking at a $20 billion to $25 billion bond sale in the US …
Shares drop at Santhera after FDA requires more trial data DMD drug
July 15, 2016Medical Communications, Research and Development Duchenne Muscular Dystrophy, FDA, santhera
Santhera Pharmaceuticals (SIX: SANN) has seen shares fall as much as 38% after the US Food and Drug Administration (FDA) …
Celgene says its Revlimid gets European approval to treat rare non-Hodgkin’s lymphoma
July 15, 2016Medical Communications, Research and Development, Sales and Marketing Celgene, European Commission, Revlimid, drug approval, drug trial, oncology
Celgene (Nasdaq: CELG) said the European Commission (EC) has approved Revlimid (lenalidomide) to treat a rare form of non-Hodgkin’s lymphoma.
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
